Skip to content

Genetic and Epigenetic Mechanisms Underlying Cocoa Health Benefits

Genetic and Epigenetic Mechanisms Underlying Cocoa Health Benefits

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02292576
Enrollment
50
Registered
2014-11-17
Start date
2012-06-30
Completion date
2014-08-31
Last updated
2014-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

volunteers

Brief summary

Evaluate if gene expression changes in SOD2 explain the health benefits of high polyphenols cocoa

Detailed description

Evaluate if gene expression changes in SOD2 explain the health benefits of high polyphenols cocoa.

Interventions

OTHERCocoa Pure

Cocoa Pure.

OTHERPlacebo

Placebo.

Sponsors

Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy adults * BMI between 18.5 and 30 kg/m2 * Sedentary to moderate physical activity habits

Exclusion criteria

* Consumption of dietary supplements, antioxidants or anti-inflammatory medication, such as aspirin, ibuprofen, naproxen, or any medication that can affect the study outcomes * Actively smoking * Suspected abuse of alcohol or illicit drugs * Significant illness within two weeks prior to study start or any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study * Subject who cannot be expected to comply with study procedures * Currently participating or having participated in another clinical trial during last 4 weeks prior to the beginning of this study * Consumption of chocolate or its derivates 24 hours before the blood sample taken

Design outcomes

Primary

MeasureTime frame
Measurement of changes in SOD2 gene expressionafter acute dose and 4 weeks of chronic dose

Secondary

MeasureTime frame
Determination of DNA methylation pattern in the chronic phase of the studyAfter 4 weeks of chronic dose
Evaluation of (-)epicatechin bioavailability in plasmaAfter 4 weeks of chronic dose
Determination of plasma antioxidant capacity as a marker of oxidative stressAfter 4 weeks of chronic dose

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026